Selection of hepatoprotector in multimorbid diseases of hepatobiliary system

Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 4

Abstract

Objective — to study of the efficacy and tolerability of Artigel complex in the treatment of patients suffering from non-alcoholic fatty liver disease (NAFLD) in combination with chronic acalculous cholecystitis (CAC) with gallbladder dysfunction (GBD) of hypotonic type. Materials and methods. The investigation involved 40 patients with NAFLD in combination with CAC and hypotonic type GBD. The mean age of patients was 42.5 ± 5.8 years. Women prevailed among patients (32 (80 %)). Besides routine clinical, laboratory, and instrumental examinations, measurements of the indices of liver functional condition and blood lipid levels were performed. Depending on the treatment type, patients were divided into two groups: patients of the main group (n = 20) received Artigel in a dose of 1 sachet 3 times daily, subjects from reference group (n = 20) received artichoke extract (300 mg capsules) 1 capsule 3 times daily. The treatment duration was 4 weeks in both groups. Results. At the baseline, there were no differences between the groups in the disease clinical manifestations, parameters of liver functional condition, blood lipid levels and sonographic criteria of gallbladder condition. After the treatment, in patients of the main group the gallbladder wall thickness was reduced in 1.9 times versus the same parameter before treatment (р < 0.05), in the reference group the reduction was in 1.3 times (р < 0.05). The portion of patients with sludge in gallbladder was 5 % in the main group and 45 % in the control group. Alanine aminotransferase activity was decreased in 2.2 times in the main group versus the baseline parameter, and in 1.4 times in the reference group; aspartate aminotransferase activity was decreased in 1.8 and 1.3 times, respectively. Alkaline phosphatase and γ-glutamyl transpeptidase activity was decreased in 1.7 and 1.5 times, respectively (р < 0.05) in patients of the main group, and showed minor decrease in patients of the reference group (р > 0.05). Total cholesterol blood level was decreased in 1.6 times (р < 0.001) in patients of the main group, and in 1.1 times (р < 0.05) in patients of the reference group; low density lipoprotein cholesterol level was decreased in 1.5 (р < 0.001) and 1.2 (р < 0.05) times, respectively. Conclusions. Administration of Artigel complex to patients with NAFLD in combination with CAC and hypotonic type GBD promotes normalization of parameters of functional condition of liver, gallbladder, and lipid metabolism.

Authors and Affiliations

V. V. Kharchenko, H. A. Anokhina

Keywords

Related Articles

Ursodeoxycholic acid in biliary pathology: current concepts

Ursodeoxycholic acid (UDCA) is a drug commonly used in clinical practice. This article is devoted to a review of research of the possibility of using UDCA for biliary system diseases. Prevention of the formation and diss...

The effectiveness of diosmectite in the treatment of irritable bowel syndrome with diarrhea

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders, characterized by abdominal pain, bloating, changes in the frequency and consistency of stool. These symptoms cannot be explained by str...

Leukemoid reactions in the gastroenterologist’s practice

Leukemic reactions (LR) are abnormal blood reactions similar to leukemic (subleukemic), but they are different in their pathogenesis; LRs never transform into leukemia. The article presents several clinical cases, the co...

A clinical case of eosinophilic esophagitis combined with macroamylasemia

Eosinophilic esophagitis is one of the most prevalent esophageal diseases and the leading cause of dysphagia and food impaction in children and young adults. The authors presented a clinical case of a patient with eosino...

Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth

Objective — to study the effects of three-month administration of the combined cytoprotector L-Betargin on the lipid and carbohydrate metabolism, biochemical markers of liver damage, the degree of its steatosis and fibro...

Download PDF file
  • EP ID EP417400
  • DOI 10.30978/MG-2018-3-36
  • Views 130
  • Downloads 0

How To Cite

V. V. Kharchenko, H. A. Anokhina (2018). Selection of hepatoprotector in multimorbid diseases of hepatobiliary system. Сучасна гастроентерологія, 0(4), 36-42. https://europub.co.uk/articles/-A-417400